• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

National Institute for Health and Care Excellence (NICE) - Articles and news items

UPDATE: The Cancer Drugs Fund

Blog, Industry news / 21 February 2017 / Niamh Louise Marriott, Digital Editor

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).  Originally introduced in 2011, The Cancer Drugs Fund (CDF) was established by the coalition Government in order to provide a means by which NHS patients in England could get cancer […]

NICE does not recommend AbbVie’s leukaemia drug

Industry news / 16 February 2017 / Niamh Marriott, Digital Editor

The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range…

Pfizer’s breast cancer drug too expensive for NHS

Industry news / 3 February 2017 / Niamh Marriott, Digital Editor

NICE has today published draft guidance which does not recommend Pfizer’s breast cancer drug palbociclib for routine funding on the NHS…

NICE approves former CDF kidney cancer drug for NHS use

Industry news / 12 January 2017 / Niamh Marriott, Digital Editor

Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma…

NICE says Roche’s trastuzumab emtansine too expensive for routine NHS use

Industry news / 29 December 2016 / Niamh Louise Marriott, Digital Editor

Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should…

NICE and FDA team up for technology collaboration

Industry news / 20 December 2016 / Niamh Louise Marriott, Digital Editor

The National Institute of Health and Care Excellence (NICE) and the United States’ Food and Drug Administration (FDA) will team up, using technology to…

pembrolizumab

Price drop and new data means NICE recommends lung cancer drug pembrolizumab

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

In earlier draft guidance, NICE’s appraisal committee had not recommended pembrolizumab as there were uncertainties about its long term benefits…

NICE recommends first-in-class severe asthma treatment

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

Mepolizumab is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms of severe asthma…

Price drop means leukaemia CDF drug will be routinely available

Industry news / 2 December 2016 / Niamh Louise Marriott, Digital Editor

Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance…

NICE recommends faecal immunochemical tests for colorectal cancer

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

FITs are considered to be accurate because unlike other tests, they use immunochemical detection methods that are specific to human haemoglobin…

Price discount helps give green light for Roche’s breast cancer drug

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision…

NICE approves three quarters of CDF drugs for routine NHS use

Industry news / 17 November 2016 / Niamh Louise Marriott, Digital Content Producer

More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS. NICE has been reappraising cancer drugs which had not been recommended in previous NICE guidance (11 drug indications in total), […]

 

Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +